Ibisubizo by'ingenzi by'ubuvuzi bwa CD7-Targeted CAR-T kuri T-ALL na T-LBL

Igerageza riherutse gukorwa mu buvuzi ryagaragaje iterambere rikomeye mu kuvura kanseri y’amaraso ya T-cell acute lymphoblastic leukemia (T-ALL) yasubiwemo cyangwa itarakira ndetse na kanseri ya T-cell lymphoblastic lymphoma (T-LBL) hakoreshejwe uburyo bwa CD7-targetted chimeric antigen receptor (CAR). Ubu bushakashatsi bwakozwe n’itsinda ry’ibitaro bya Hebei Yanda Lu Daopei n’ikigo cya Lu Daopei Institute of Hematology, bwakorewe ku barwayi 60 bahawe dose imwe y’uturemangingo twa T twatoranyijwe karemano twa CD7 CAR (NS7CAR).

Ibisubizo by’igerageza birashimishije cyane. Ku munsi wa 28, 94.4% by’abarwayi babonye ubumuga bw’igufwa (CR) mu musemburo w’amagufwa. Byongeye kandi, mu barwayi 32 barwaye indwara yo hanze ya medullary, 78.1% bagaragaje ko babyitabiriye neza, aho 56.3% babonye ubumuga bw’igufwa ryuzuye na 21.9% babonye ubumuga bw’igufwa ry’igice. Igipimo cy’ubuzima bw’imyaka ibiri muri rusange n’ubuzima budafite iherezo bwari 63.5% na 53.7%, uko bikurikirana.

Ubu buvuzi bushya buzwi cyane kubera umutekano wabwo, aho indwara ya cytokine release syndrome igaragara ku barwayi 91.7% (abenshi mu cyiciro cya 1/2), kandi uburozi bw'imitsi bwagaragaye kuri 5% by'abarwayi. Byongeye kandi, ubushakashatsi bwagaragaje ko abarwayi bakomeje gutera imiti nyuma yo kugera kuri CR bari bafite igipimo cyo kubaho kidahinduka ugereranyije n'abatabikoze.

Isosiyete yacu irimo kandi gusuzuma ubushobozi bwo kuvura CD7 CAR-T cell therapy ikoresheje ibicuruzwa byacu bwite, bigamije gutanga umusanzu mu guteza imbere uburyo bwo kuvura kanseri ya T-cell.

Ibi byavumbuwe bigaragaza ubushobozi bw’ubuvuzi bwa selile za CAR-T zigamije CD7 mu gutanga icyizere gishya ku barwayi bafite T-ALL na T-LBL badashobora kuvura cyangwa basubiye mu ndwara, bikaba ari intambwe ikomeye mu rugamba rwo kurwanya izi ndwara zikomeye.